|
Delayed
Nasdaq
17:35:39 28/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.460 USD | +3.55% |
|
+3.55% | +11.45% |
| 10-12 | MediciNova Phase 2 Trial in Fatty Liver Disease Drug Misses Primary Endpoints | MT |
| 10-12 | Medicinova, Inc. Provides Update on Mn-001 Phase 2 Clinical Trial Results and Mn-166 Combat-Als Trial | CI |
| Market Cap | 69.4M 62.29M 57.51M 52.15M 97.48M 6.59B 98.68M 690M 274M 3.46B 261M 255M 10.96B | P/E 2026 * |
-5.53x | P/E 2027 * | -3.16x |
|---|---|---|---|---|---|
| Enterprise Value | 69.4M 62.29M 57.51M 52.15M 97.48M 6.59B 98.68M 690M 274M 3.46B 261M 255M 10.96B | EV / Sales 2026 * |
95.1x | EV / Sales 2027 * | 208x |
| Free-Float |
97.14% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MNOV | Delayed | |
Japan Exchange
| 4875 | Delayed | |
|
CBOE
| MNOV | Real-time |
| 1 day | +3.55% | ||
| 1 week | +3.55% | ||
| Current month | -12.84% | ||
| 1 month | -30.48% | ||
| 3 months | +9.77% | ||
| 6 months | +7.35% | ||
| Current year | +11.45% |
| 1 week | 1.38 |  | 1.47 |
| 1 month | 1.36 | | 2.06 |
| Current year | 1.22 | | 3.9 |
| 1 year | 1.17 | | 3.9 |
| 3 years | 1.12 | | 3.9 |
| 5 years | 1.12 | | 4.65 |
| 10 years | 1.12 | | 14.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuichi Iwaki
CEO | Chief Executive Officer | 76 | 01/08/2005 |
Jason Kruger
DFI | Director of Finance/CFO | 49 | 16/06/2022 |
Kazuko Matsuda
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/09/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuichi Iwaki
CHM | Chairman | 76 | 26/09/2000 |
Kazuko Matsuda
BRD | Director/Board Member | 60 | 24/07/2019 |
Hideki Nagao
BRD | Director/Board Member | 69 | 01/09/2004 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/25/26 A | 3D Investment Partners Pte. Ltd.
| Sell | Company | -640,000 | 1.3003% | |
| 1/16/26 A | Free | Chief Technology Officer | 350,000 | 0.7122% | ||
| 1/16/26 A | Free | Chief Executive Officer | 450,000 | 0.9156% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.55% | +3.55% | +20.66% | -25.51% | 69.4M | |
| +0.65% | -3.56% | +33.53% | +60.50% | 63.48B | |
| +2.61% | +2.14% | +12.77% | +83.68% | 54.55B | |
| -0.98% | +1.35% | +10.84% | +102.89% | 53.59B | |
| +3.90% | +1.24% | +28.39% | +58.08% | 44.75B | |
| +2.55% | -3.02% | +18.29% | +100.85% | 41.62B | |
| +0.74% | -3.74% | +221.49% | +919.13% | 39.91B | |
| -0.74% | -4.46% | +11.00% | +44.65% | 32.47B | |
| +25.98% | +40.27% | +96.79% | +84.58% | 26.7B | |
| +3.72% | -6.23% | +26.01% | -8.28% | 23.36B | |
| Average | +4.19% | -0.23% | +47.98% | +142.06% | 38.05B | |
| Weighted average by Cap. | +3.14% | -0.48% | +46.86% | +160.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 730K 655K 605K 549K 1.03M 69.34M 1.04M 7.25M 2.88M 36.34M 2.74M 2.68M 115M | 333K 299K 276K 250K 468K 31.66M 474K 3.31M 1.32M 16.6M 1.25M 1.22M 52.63M |
| Net income | -12.89M -11.57M -10.69M -9.69M -18.11M -1.22B -18.33M -128M -50.88M -642M -48.4M -47.36M -2.04B | -25.98M -23.32M -21.53M -19.52M -36.49M -2.47B -36.94M -258M -103M -1.29B -97.53M -95.44M -4.1B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | $1.460 | +3.55% | 8,268 |
| 27/10/26 | $1.410 | +0.71% | 37,751 |
| 26/10/26 | $1.400 | +0.72% | 89,906 |
| 23/10/26 | $1.390 | -1.42% | 25,509 |
| 22/10/26 | $1.410 | 0.00% | 30,488 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MNOV Stock
Select your edition
All financial news and data tailored to specific country editions
